Finanzen von Clearmind Medicine Inc (CMND)CMNDClearmind Medicine Inc

Evaluating the bottom line, Clearmind Medicine Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -114.61%, provide a clear picture of how effectively CMND converts its operational activities into shareholder value.

In the context of the broader market, CMND competes directly with industry leaders such as AQMS and FMST. With a market capitalization of $2.75M, it holds a significant position in the sector. When comparing efficiency, CMND's gross margin of N/A stands against AQMS's N/A and FMST's N/A. Such benchmarking helps identify whether Clearmind Medicine Inc is trading at a premium or discount relative to its financial performance.

Clearmind Medicine has shown a consistent negative net income, with the latest quarter reporting a net income of -3,854,583 USD and an EPS of -328.38, indicating ongoing financial difficulties. The current ratio has improved to 4.79, suggesting better liquidity, but the overall financial health remains concerning.